# A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan

Source: https://onco.cc/trials/nct01882868/  
OnCo record `nct01882868` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ziv-aflibercept, Irinotecan and Fluorouracil in Colorectal cancer, run by Sanofi, completed.

## Summary

A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan is a phase 2 interventional study registered as NCT01882868 by Sanofi, with 62 participants recorded, started 2013-07 and reaching its primary completion in 2015-08. Interventions recorded: Aflibercept, Levofolinate, Irinotecan, 5-FU. Conditions recorded: Colorectal Cancer Metastatic.

Linked to the drug Ziv-aflibercept because the registry names it among its interventions and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01882868
- Phase: 2
- Setting: A Single-Arm Phase II Study in Japan to Assess the Efficacy and Safety of Aflibercept Administered Every Two Weeks in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Who Progressed During or Following an Oxaliplatin-Based Regimen
- Sponsor: Sanofi
- Enrolled: 62

## Sources

- ClinicalTrials.gov NCT01882868: https://clinicaltrials.gov/study/NCT01882868

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Irinotecan (and liposomal irinotecan)](https://onco.cc/drugs/irinotecan/), [Ziv-aflibercept](https://onco.cc/drugs/ziv-aflibercept/)
- companies: [Sanofi](https://onco.cc/companies/sanofi/)

---
JSON: https://onco.cc/api/v1/entities/nct01882868.json